"Viking Therapeutics Leads Weight-Loss Drug Fervor with Stock Surge"

Eli Lilly's stock is on the rise as it forms a flat base amidst increasing competition in the weight-loss drug space, particularly with Viking Therapeutics' promising test results for its experimental pill. Despite this, analysts remain optimistic about Lilly's weight-loss drugs, Zepbound and Wegovy, with expectations of significant sales growth. The company is also developing new pills targeting GLP-1 and GIP, aiming for stronger weight loss. Eli Lilly stock has shown strength in technical and fundamental measures, remaining above its 50-day moving average and boasting a strong Relative Strength Rating and Composite Rating.